Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...

My colleague Clarissa Jan-Lim wrote a great explainer on the Trump administration's efforts to root out DEI programs from the federal government, including a memo demanding a plan to fire federal ...

Trump signed executive orders on Monday and Tuesday aimed to end DEI programs within the federal government and rescind many of the Biden administration orders that put some of DEI programs in ...

The memorandum, issued by the Office of Personnel Management on Tuesday, is a part of President Donald Trump’s aggressive reversal of the federal DEI policies of his predecessor. Federal ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

The FBI shuttered its diversity, equity and inclusion (DEI) office last month, according to the law enforcement agency. “In recent weeks, the FBI took steps to close the Office of Diversity and ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

I hear from them all the time. “Add one more to your list of aggrieved white males,” a reader wrote to me recently. The man, a 64-year-old electrical engineer in Florida, said a manager at ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

Several companies have rolled back DEI initiatives Trump has openly opposed DEI efforts Democratic attorneys general want the company to reconsider Walmart is one of the latest corporations ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...